FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
GeoVax Labs, Inc. Stock AnalysisComprehensive stock analysis for GeoVax Labs, Inc. (GOVXW) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisGOVXW
GOVXW
GeoVax Labs, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
GOVXW
Home🔹Stocks🔹GeoVax Labs, Inc.

GeoVax Labs, Inc.

GOVXW•NASDAQ

GeoVax Labs, Inc.

GOVXW•NASDAQ
Market cap
$88.76K
Sentiment

Your view on GOVXW

Mkt Cap
$88.76K
Sentiment
Your view
GOVXW
GeoVax Labs, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
GOVXW
Company Overview

Overview

What the company does, where it operates, and who runs it.

About GeoVax Labs, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
David Alan Dodd
Headquarters
1900 Lake Park Drive, Smyrna, GA, US
Industry
Biotechnology
Sector
Healthcare
CEO
David Alan Dodd
Headquarters
1900 Lake Park Drive, Smyrna, GA, US
Description

GeoVax Labs, Inc. is a clinical-stage biotechnology firm dedicated to creating human vaccines and immunotherapies. The company's core mission involves tackling a range of infectious diseases and various solid tumor cancers. Their innovative approach is centered on a proprietary modified vaccinia ankara virus-like particle (MVA-VLP) vaccine platform. The company's pipeline includes diverse preventive vaccine candidates aimed at combating critical pathogens such as COVID-19, human immunodeficiency virus (HIV), Zika virus, malaria, and hemorrhagic fever viruses like Ebola, Sudan, Marburg, and Lassa. In parallel, GeoVax is advancing therapeutic vaccines designed to address existing conditions, including HIV, chronic Hepatitis B infections, and solid tumor malignancies. Key programs include GEO-CM04S1, a COVID-19 preventive vaccine candidate currently in Phase 2 clinical trials, and Gedeptin, a novel, patented product in Phase 1/2 clinical trials for treating advanced head and neck squamous cell carcinoma, which is also being explored for broader solid tumor applications. Additionally, the company is developing GEO-CM02, a pan-coronavirus vaccine. The preclinical stage features several other promising candidates, such as GEO-ZM02 for Zika, GEO-MM02 for malaria, GEO-EM01 for fever viruses (Ebola, Sudan, and Marburg), and GEO-LM01 targeting Lassa fever. GeoVax maintains strategic collaborations and partnership agreements with prominent institutions, including the National Institute of Allergy and Infectious Diseases (NIAID) within the National Institutes of Health, the U.S. Department of Defense, Emory University, and the Burnet Institute. Established in 1988, GeoVax Labs, Inc. operates from its headquarters in Smyrna, Georgia.

FRC Research

Media

Infographics, videos, and posts covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

FRC's fair value estimate for GeoVax Labs, Inc., and the rating behind it. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Valuation, profitability, liquidity and leverage ratios for GeoVax Labs, Inc.. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Dividend history, yield and payout sustainability for GeoVax Labs, Inc.. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Reported vs. expected earnings history for GeoVax Labs, Inc.. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Income statement, balance sheet and cash flow history for GeoVax Labs, Inc.. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

GeoVax Labs, Inc. valued side by side against its closest peers. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Which institutions hold GeoVax Labs, Inc., and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

Buying and selling by GeoVax Labs, Inc. executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

U.S. Senate disclosures naming GeoVax Labs, Inc.. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.

House Trading

U.S. Representative disclosures filed under the STOCK Act.

U.S. House of Representatives disclosures naming GeoVax Labs, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.

News

Latest headlines and market coverage.

Latest headlines and company announcements for GeoVax Labs, Inc.. Press releases and market coverage, newest first.

News

Latest Market News